Is this a good example of a momentum burst set up?
The price has made a 4% move today where I have made the buy.
The preceding 3 days have been small range days and in all 3 sessions the market closed below the open i.e. down days.
There has been an orderly consolidation with price moving sideways after an impulse move from 17.90s area.
Today's move is the...
Found a cup on this volatile stock. Previous cup made it to the 62% mark which is impressive.
Very weird handle. Seems to be in a broadening pattern and then is in an ascending triangle pattern. I would say wait to break cup top which should be soon.
T1: 38% depth at $39.50 and 62% depth at $44.53
Hello traders, MYRIAD GENETICS is in a fake bearish configuration with a large buying volume executed and a water carrying candle accompanied by a very strong lower leg. Looking at the TIMEFRAME M1 we see a marubozu with a large negotiated purchase volume, it goes towards the base of the bollinger for a new test. Then go to the highest to arrive on the VWAP once...
MYGN: Myriad Genetics, Inc.
2020-05-11 07:05:10
Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
I thought about it and didn't publish this because my earnings plays for today didn't play out like it should have. CENT and USX both lost money but apparently "beat estimates", which is hilarious when the estimate is a loss. You'd think they were tech companies or something. At least CENT went down after a short squeeze rally, and we nailed XYL. In the end I...
MYGN has been a player for a while, large company, with actual earnings, however litigation and companies are generally a bad thing. "healthy" enough of a chart for me to participate, but I will not have much patience to the downside, stop in place.
**Long this last collapse, limited in size... confidence is enough to buy, not enough to bet the farm
MYGN: Myriad Genetics, Inc.
2019-10-23 17:40:52
FDA Approves Myriad’s myChoice® CDx Test to Help Identify Women Eligible for Treatment with Zejula® in Late-line Ovarian Cancer
I think this stock will recover some of it's losses, regardless of the outcome of the potential FDA restrictions on drug suggestions. The stock has a solid business model and the company has said they are seeing increased demand. This new fields of genetics testing still needs to establish itself in the healthcare payer ecosystem, which presents some risk, but all...
MYGN is setting up a long term H&S. An aggressive sell option is triggering today on the close below the old pivot low with the stop past the head. H&S will not trigger until a break of the neckline near $27. Aggressive right shoulder buy and sell's fail, but the greatly increased risk/reward can help offset.
MYGN Price broke out from 2 1/2 months of a base formation. A price gap of nearly 10% with very high volume occurred as a result of better-than-expected earnings. Unfortunately, we shouldn't expect the Tight Flag pattern to be powerful, since it is coming out of a base formation pattern, and not a powerful uptrend, but there should be enough upside potential to...
